Bill Meagher

Bill Meagher's focus with The Deal is on small and microcap equity finance, healthcare and biotechnology, PIPEs, and companies going public. His work has appeared in newspapers and magazines throughout California as well as on PBS, “60 Minutes,” ABC News and CNBC. Meagher has also written video scripts and produced national events for a non-profit educational organization and ghost written two books.

Recent Articles By The Author

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets

Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

Congress Sets Opioid Hearing Next Month for Drug Distributors

Congress Sets Opioid Hearing Next Month for Drug Distributors

A House committee trying to understand how the opioid crisis came to be and what to do next has set a May 8 hearing for drug distributors to explain their role.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

McKesson Lawsuit Puts Drug Distributors Back Into Harsh Public Spotlight

McKesson Lawsuit Puts Drug Distributors Back Into Harsh Public Spotlight

McKesson and other drug distributors are having a difficult time steering clear of controversy, with the latest blow a lawsuit alleging McKesson has violated the False Claims Act.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.